Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Influence of FK 506 (tacrolimus) on circulating CD4 <sup>+</sup> t cells expressing cd25 and cd45ra antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial

Lemster, B and Huang, LL and Irish, W and Woo, J and Carroll, PB and Abu-Elmagd, K and Rilo, HR and Johnson, N and Russell-Hall, R and Fung, JJ and Starzl, TE and Eidelman, B and Thomson, AW (1994) Influence of FK 506 (tacrolimus) on circulating CD4 <sup>+</sup> t cells expressing cd25 and cd45ra antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. Autoimmunity, 19 (2). 89 - 98. ISSN 0891-6934

[img]
Preview
PDF
Accepted Version
Available under License : See the attached license file.

Download (1MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

We have taken the opportunity of a clinical trial of the potential efficacy and safety of FK 506 (tacrolimus) in chronic progressive multiple sclerosis ( MS) to examine the influence of this potent new immunosuppressant on circulating T-lymphocytes in an otherwise healthy non-transplant population. Peripheral blood levels of subsets of CD4 + T lymphocytes expressing the activation molecule interleukin-2 receptor (p55 α chain; CD25) or the CD45RA isoform were determined sequentially in 19 patients that were treated continuously with oral FK 506 (starting dose 0.15 mg/kg/day) for 12 months. No significant change in the proportion of circulating CD25 + CD4 + cells was observed over the study period in which the mean trough plasma FK 506 level rose from 0.3 ±0.2 to 0.5 ±0.4 ng/ml. There was also no significant effect of FK 506 on the percentage of CD45RA + CD4 + cells in the peripheral blood at 12 months compared with pretreatment values. Analysis of a subgroup of 7 patients, who showed a sustained reduction in CD25 + CD4 + cells and a reciprocal increase in CD45RA* CD4 * cells for at least 6 months after start of treatment, did not reveal any difference in disability at one year compared with the treatment group as a whole. The side effects of FK 506 were mild and the overall degree of disability estimated by the mean Kurtzke expanded disability status scale (EDSS) score or the ambulation index did not deteriorate significantly in the 19 patients studied over the 12 months of FK 506 administration. © 1994 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Status: Published
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Lemster, B
Huang, LL
Irish, W
Woo, J
Carroll, PB
Abu-Elmagd, K
Rilo, HR
Johnson, N
Russell-Hall, R
Fung, JJ
Starzl, TEtes11@pitt.eduTES11
Eidelman, B
Thomson, AW
Centers: Other Centers, Institutes, or Units > Thomas E. Starzl Transplantation Institute
Date: 1 January 1994
Date Type: Publication
Journal or Publication Title: Autoimmunity
Volume: 19
Number: 2
Page Range: 89 - 98
DOI or Unique Handle: 10.3109/08916939409009536
Institution: University of Pittsburgh
Refereed: Yes
ISSN: 0891-6934
Other ID: uls-drl:31735062126184, Starzl CV No. 1766
Date Deposited: 08 Apr 2010 17:30
Last Modified: 13 Oct 2017 22:57
URI: http://d-scholarship.pitt.edu/id/eprint/5152

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item